Circulation, Volume 150, Issue Suppl_1, Page A4141352-A4141352, November 12, 2024. Background:Major adverse cardiovascular events (MACE), including myocardial infarction, acute coronary syndrome, ischemic heart disease requiring revascularization, stroke, and heart failure, have been documented as significant contributors to mortality in cancer survivors. Coronary artery calcium (CAC) can predict MACE in non-cancer populations, while calcium in the aorta (CA) has not been evaluated as a prognostic marker. Every patient diagnosed with cancer undergoes a standard-of-care Positron Emission Tomography-Computed Tomography (PET-CT) or a chest CT before the initiation of chemotherapy.Hypothesis:To determine whether the CAC or CA of patients with Hodgkin’s or non-Hodgkin’s lymphoma, derived from standard-of-care PET-CT/chest CT, can predict the incidence of MACE.Methods:Patients treated with anthracycline-based chemotherapy, diagnosed and followed from January 1, 2013, through June 30, 2023, were included. Patients who did not undergo a PET-CT or CT, and/or developed MACE before treatment initiation were excluded. Univariate and multivariate adjusted Cox regression models were employed to assess whether the presence of CAC, CA, or CAC-CA was associated with the development of MACE. Calcium was retrospectively quantified using TeraRecon software (Durham NC) and categorized as: 0, 1-99, and >100. Outcome analyses was estimated using the Kaplan-Meier method.Results:326 patients were included, mean age of 55 years (range: 52-60), predominantly male 201 (61%) and white 314 (96%), CAC was found in 89 patients and CA in 140. In the univariate regression model, a statistically significant association was found with values >100 for CA, CAC and CAC-CA with the risk of MACE. (Fig 1a/b/c). CAC equal to 0 demonstrated a significant protective effect against MACE. (Fig 1a). In the multivariable analysis, these associations persisted even after adjusting for comorbidities. (Table 1).Conclusion:CAC, CA and CAC/CA >100 in the standard-of-care CT/PET CT are predictors of MACE in lymphoma patients undergoing anthracycline treatment, a CAC equal to 0 has protective effect, these relationships remained statistically significant after adjusting for comorbidities.
Risultati per: Nuovi trattamenti nei linfomi non Hodgkin a cellule B
Questo è quello che abbiamo trovato per te
Geni sintetici imitano il modo in cui le cellule costruiscono tessuti e strutture
La ricerca degli atenei Tor Vergata e Ucla apre la strada ad ampie applicazioni in medicina e biotecnologia
Tumori, un doppio colpo manda al tappeto le cellule difettose
La scoperta apre a terapie più mirate
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
New England Journal of Medicine, Volume 391, Issue 15, Page 1379-1389, October 17, 2024.
Therapy for Hodgkin’s Lymphoma — Can It Get Any Better?
New England Journal of Medicine, Volume 391, Issue 15, Page 1452-1454, October 17, 2024.
La nocciola possibile antitumorale, studio su cellule del fegato
Condotto dall’Enea. Biomolecole ne inibiscono la proliferazione
Melanoma, immunoterapia locale uccide tumore e recluta cellule
Dal sistema immunitaria, per contrastare metastasi e recidive
Cellule riprogrammate imparano a colpire il tumore al cervello
Modificate geneticamente abbattono i tassi di recidività
Terapia derivata dalle cellule staminali contro il cancro al fegato resistente al trattamento
Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma
This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Sa1755 THE EVOLVING TRENDS OF HODGKIN'S AND NON-HODGKIN'S LYMPHOMAS AMONG HOSPITALIZED PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN THE BIOLOGIC TREATMENT ERA: AN ANALYSIS OF THE NATIONAL INPATIENT SAMPLE DATABASE.
EP77 PARANEOPLASTIC CHOLESTASIS FROM CLASSIC HODGKIN LYMPHOMA
L’intelligenza artificiale prevede con precisione i risultati dei trattamenti
ACP: linee guida cliniche per i nuovi trattamenti del diabete tipo 2
Mielomi e linfomi, al via 2 protocolli sperimentali con le CAR-T
All’Humanitas. Con nuove terapie speranze di cura per il 70% dei pazienti
Linfoma diffuso a grandi cellule, nuovo protocollo al Pascale
Promo centro in Italia a praticarlo, è il terzo nel mondo